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Abstract  Atypical  haemolytic  uraemic  syndrome  is  one  of  the  main  variants  of  thrombotic
microangiopathy,  and  is  characterised  by  excessive  complement  activation  in  the  microvas-
culature.  It  is  also  characterised  by  the  clinical  triad;  non-immune  haemolytic  anaemia,
thrombocytopenia,  and  acute  renal  failure.  In  addition,  60%  of  patients  have  mutations  in  the
genes encoding  complement  regulators  (factor  H,  factor  I,  membrane  cofactor  proteins,  and
thrombomodulin),  activators  (factor  B  and  C3),  as  well  as  autoantibodies  against  factor  H.  Multi-
ple factors  are  required  for  the  disease  to  manifest  itself,  including  a  trigger  and  gene  mutations
with adequate  penetration.  Being  one  of  the  differential  diagnoses  of  preeclampsia--eclampsia
and HELLP  syndrome  means  that  the  clinician  must  be  familiar  with  the  disease  due  to  its  high
mortality, which  can  be  modiﬁed  with  early  diagnosis  and  comprehensive  treatment.
© 2016  Academia  Mexicana  de  Cirug´ıa  A.C.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE Síndrome  urémico  hemolítico  atípico  en  el  embarazo
Síndrome  urémico
Resumen  El  síndrome  hemolítico  urémico  atípico  es  una  variante  de  la  microangiopatíahemolítico  atípico;
Microangiopatía
trombótica;
Embarazo
trombótica,  caracterizado  por  una  excesiva  activación  del  complemento.  Se  caracteriza  por  pre-
sentar anaemia  hemolítica  no  autoinmune,  trombocitopenia  y  falla  renal  aguda.  Se  ha  observado
que el  60%  de  los  pacientes  presentan  mutaciones  en  los  genes  que  codiﬁcan  al  complemento,
tanto reguladores  (factor  H,  factor  I,  cofactor  de  proteínas  de  membrana  y  trombomodulina),
 Please cite this article as: Pérez-Calatayud ÁA, Briones-Gardun˜o JC, del Pilar Álvarez-Goris M, Sánchez Zamora R, Torres Aguilar AA,
endoza-Morales RE. Síndrome urémico hemolítico atípico en el embarazo. Cir Cir. 2016;84:344--349.
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activadores  (factor  B  y  C3)  como  autoanticuerpos  contra  el  factor  H.  Se  requiere  la  presencia  de
múltiples factores  para  su  manifestación,  estos  incluyen:  un  disparador  y  mutaciones  de  genes
con la  penetrancia  adecuada.  Es  necesario  que  el  clínico  esté  familiarizado  con  la  enfermedad,
ya que  presenta  una  elevada  morbimortalidad  que  puede  ser  modiﬁcada  si  se  identiﬁca  de
manera temprana  y  se  da  un  tratamiento  oportuno.
© 2016  Academia  Mexicana  de  Cirug´ıa  A.C.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Atypical  haemolytic  uraemic  syndrome  is  a  variant  of
the  thrombotic  microangiopathy  which  is  characterised  by
the  following  clinical  triad:  non-autoimmune  haemolytic
anaemia,  thrombocytopenia  and  acute  kidney  failure.1,2
It  is  characterised  by  an  irregularity  of  the  comple-
ment  system,  caused  by  genetic  mutation  of  its  inhibitors.2
Malignant  hypertension,  septicaemia,  auto-immune  disorder
(lupus,  scleroderma),  streptococcal  infections,  pregnancy,
HELLP  syndrome  and  cancer  may  be  the  cause  of  this
syndrome.3
Traditionally,  haemolytic  uraemic  syndrome  is  classiﬁed
in  2  ways:  typical  haemolytic  uraemic  syndrome  which  peaks
in  incidence  in  children  and  is  caused  by  enteric  infections
secondary  to  bacteria  which  are  producers  of  the  Shiga  toxin
(Fig.  1)  and  atypical  haemolytic  uraemic  syndrome  which  in
50--60%  of  cases  is  associated  with  patients  with  gene  muta-
tions  within  the  complement  system,  which  in  the  majority
of  patients  leads  to  terminal  chronic  kidney  failure  and  the
need  for  a  kidney  transplant.4--6
Pregnancy  may  be  a  trigger  of  this  disease,  particularly
during  the  postnatal  period.  This  is  the  result  of  the  comple-
ment  system  playing  a  signiﬁcant  role  in  the  physiopathology
of  pregnancy.  It  increases  to  prevent  the  damage  caused
by  the  placenta  through  the  trophoblastic  expression  of
complement  regulatory  proteins,  known  as  the  aggravating
factor  in  degradation,  the  membrane  cofactor  protein  (MCP)
and  CD59.5--7
There  is  a  reduction  of  these  proteins  in  the  postnatal
period,  or  a  reduction  in  the  majority  complement  proteins,
which  lead  to  the  appearance  of  disease.7
Shiga toxin
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Glomerular
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Figure  1  Haemolytic  uraemic  syndrome  secondary  to  enteric
infection  caused  by  the  Shiga  toxin.
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apidemiology
hrombotic  microangiopathy  associated  with  pregnancy
P-TMA)  has  an  incidence  of  1  case  in  every  250,000
regnancies.8--10 There  are  reports  of  an  incidence  of  atyp-
cal  haemolytic  uraemic  syndrome  of  2  cases  for  every
,000,000  inhabitants.11 In  women  of  reproductive  age
he  phenotype  of  atypical  haemolytic  uraemic  syndrome
resents  in  late  pregnancy  or  in  the  immediate  postpartum
eriod.11 In  10%  of  patients  with  this  syndrome,  the  onset  of
regnancy  is  the  trigger.12
hysiopathology
he  complement  system  is  one  of  the  main  mechanisms
nvolved  in  immunity  measured  by  antibodies,  and  is  con-
idered  to  be  a  bridge  between  innate  and  adaptive
mmunity,  which  offers:  protection  against  bacterial  infec-
ion,  enhancement  of  the  elimination  of  immune  complexes
nd  inﬂammatory  products,  protection  against  external
gents  and  the  regulation  of  cellular  apoptosis.13 There
re  3  independent  pathways  for  its  activation:  classical,
ectin  and  alternative.14 Activation  needs  to  be  regulated  to
revent  tissue  damage,  particularly  when  activated  by  the
lternative  pathway.15 In  the  majority  of  patients  affected
y  atypical  haemolytic  uraemic  syndrome  its  development
s  related  to  uncontrolled  activation  of  the  complement
athway  and  with  a  growing  number  of  genetic  mutations
hich  have  already  been  identiﬁed  for  the  activation  of
his  syndrome.15 These  mutations  are  observed  in  the  genes
hich  regulate  the  function  of  the  complement,  such  as
omplement  H  (FCH)  factor  inhibitors.  Richard16 identiﬁed
he  importance  of  the  mutations  of  this  gene  as  a  cause
f  haemolytic  uraemic  syndrome.  He  discovered  mutations
f  the  FCH  gene  in  exons  18--20  of  2  familial  and  3  spo-
adic  patients  out  of  the  19  familial  and  31  sporadic  patients
tudied.15 Furthermore,  this  study  showed  that  the  familial
aemolytic  uraemic  syndrome  is  a  heterogeneous  condition.
odríguez17 discovered  that  the  mutations  in  the  FCH  reg-
lators,  the  complement  I (FCH)  factor  and  PCM  led  to  the
oss  of  the  complement  functioning,  whilst  those  of  C3  acti-
ated  functioning  (Fig.  2).  PCM  (CD46)  is  a transmembrane
egulatory  complement  which  is  broadly  expressed  as  FCH,
nd  Richards18 discovered  a  PCM  (CD46)  mutation  in  individ-
als  of  3  familials,  who  presented  a  deletion  of  2  amino
cids  (D237/S238)  in  the  familial  1  (heterozygote)  and  a
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eplacement  S206P,  in  the  familial  2  (heterozygote)  and  3
homozygote),  which  conﬁrmed  that  the  deregulation  of
he  complement  predisposes  the  development  of  thrombotic
icroangiopathy  and  that  patients  under  review  for  these
efects  could  provide  preventative  treatment  strategies  in
atients  with  this  type  of  mutation.18 The  FCH  mutation
ccurs  in  6--20%  of  patients  with  atypical  haemolytic  uraemic
yndrome  and  the  mutation  in  CD46  in  10%  of  patients.18--22
Factor  I  is  an  inhibitor  of  all  complement  pathways.  It  has
he  capacity  to  degrade  C3b  and  C4b  activated  proteins  in
he  present  of  cofactors  such  as  FCH,  CD46,  among  others.
ncomplete  deﬁciency  of  factor  I  is  also  associated  with  the
evelopment  of  atypical  haemolytic  uraemic  syndrome.19
The  increase  in  the  function  of  the  complement  sys-
em  factors,  such  as  factors  B  and  C3  may  also  cause  the
xpression  of  this  syndrome.20--22 Autoantibodies  against  FCH
ncrease  the  risk  for  its  expression  but  the  disease  has
n  associated  incomplete  penetration  which  is  different  to
ach  mutation  and  therefore  not  all  carriers  of  mutations
ill  develop  atypical  haemolytic  uraemic  syndrome,22,23 only
hose  women  with  a  genetic  predisposition  and  an  external
rigger.24
typical uraemic haemolygic syndrome and
regnancy
he  pathogenesis  of  atypical  haemolytic  uraemic  syndrome
n  pregnancy  remains  uncertain,  it  appears  in  21%  of  adult
omen  and  in  79%  of  them  it  presents  during  the  postnatal
eriod.
The  risk  of  presenting  with  gestational  atypical
aemolytic  uraemic  syndrome  is  greatest  during  sec-
nd  pregnancy.  In  a  retrospective  study  Fakhouri25 found
bnormalities  of  the  complement  system  in  18  out  of  21
atients.  Findings  did  not  differ  among  patients  with  preg-
ancy  related  or  not  related  to  atypical  haemolytic  uraemic
yndrome.  Mutations  in  the  domain  structures  SCR19--20
f  factor  H  were  less  frequent  in  patients  with  gestational
F
d
ecomplement  cascade.
typical  haemolytic  uraemic  syndrome  compared  with
typical  haemolytic  uraemic  syndrome.  Pregnancies  with
omplement  anomalies  presented  with  complications
haracterised  by  foetal  losses  and  preeclampsia  in  4.8  and
.7%,  respectively.
ifferential diagnosis
icroangiopathy  may  be  the  manifestation  of  many  dis-
ases:  connective  tissues  diseases,  cancer  or  may  present
n  post  transplant  patients.  However,  it  predominates  in
hrombotic  thrombocytopenic  purpura,  atypical  haemolytic
raemic  syndrome,  and  haemolytic  uraemic  syndrome
aused  by  the  Shiga  toxin  from  Escherichia  coli. Thrombotic
hrombocytopenic  purpura  is  associated  with  a  deﬁciency
f  ADAMTS13,  and  both  types  of  uraemic  syndrome  are
haracterised  by  the  presence  of  haemolytic  anaemia,
hrombocytopenia  and  multiple  organ  failure;26 atypical
aemolytic  uraemic  syndrome,  presents  during  the  post-
atal  period  whilst  thrombotic  thrombocytopenic  purpura
ssociated  with  deﬁciency  of  ADAMTS13  presents  during
regnancy.26
A  key  point  for  differentiating  between  atypical
aemolytic  uraemic  syndrome  and  thrombotic  thrombocy-
openic  purpura  is  to  highlight  the  presence  of  a  severe
eﬁciency  of  ADAMTS13,  which  should  be  greater  than
--10%.26--28 In  cases  where  the  activity  of  ADAMTS13  can-
ot  be  calculated,  Coppo  showed  that  the  presence  of  a
latelet  count  of  30  ×  109/l  and  a  creatine  count  below
.26  mg/dl  is  associated  with  deﬁciency  of  ADAMTS13  and
ence  with  the  diagnosis  of  thrombotic  thrombocytopenic
urpura  (Table  1).29
The  presence  of  acute  kidney  failure  which  requires
eplacement  kidney  transplant  therapy  is  found  to  be  asso-
iated  with  germinal  mutations  of  the  genes  FCH,  CD  46,
CI.30
Differential  diagnosis  of  microangiopathy  includes:
isseminated  intravascular  coagulation,  preeclampsia--
clampsia  and  HELLP  syndrome.31
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Table  1  Differential  diagnosis  of  atypical  haemolytic  uraemic  syndrome  and  other  microangiopathies.
Preeclampsia  HELLP  syndrome  Thrombocytopenic  purpura  AHUS
Hypertension  Very  common Very  common  Rare/absent  Common
Proteinuria Constant  Constant  Rare/absent  Constant
Jaundice Rare/absent  Rare/absent  Rare/absent  Rare/absent
Neurological  symptoms  Common  Very  common  Common  Rare/absent
Abdominal pain  Rare/absent  Very  common  Rare/absent  Rare/absent
Thrombocytopenia  Common  Constant  Constant  Constant
Haemolisis Rare/absent  Constant  Constant  Constant
Raising of  total  bilirrubin  Common  Constant  Constant  Constant
Raising of  transaminase  level Common  Constant  Rare/absent  Rare/absent
In the  trimester 3rd  3rd  2nd  or  3rd Postnatal
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vAHUS: atypical haemolytic uraemic syndrome.
Diagnosis
In  patients  with  suspected  atypical  haemolytic  uraemic  syn-
drome,  the  initial  step  is  to  conﬁrm  the  presence  of  anaemia
and  thrombocytopenia  and  carry  out  differential  diagnosis
with  diseases  which  may  present  these  conditions.  Initial
laboratory  studies  should  include  a  haematic  biometry  to
document  anaemia  and  thrombocytopenia,  the  presence  of
fragmented  cells  in  blood  smears,  to  determine  the  presence
of  a  high  lactate  dehydrogenase  as  part  of  the  haemolytic
anaemia  study,  the  raising  of  creatinine,  the  determination
of  ADAMTS  13,  and  a  stool  test  and  PCR  detection  for  E.  coli
0157.32
Diagnosis  is  complex  since  the  majority  of  tests  are  not
available  in  obstetrics  services.31 In  high  risk  patients  or  with
genetic  load  for  atypical  haemolytic  uraemic  syndrome  a
DNA  test  is  required  to  search  for  mutations  in  C3,  FB,  FH,
FI,  CD46. Formula  testing  in  kinase  diacylglycerol    (DGK)
is  also  proposed,  as  this  encodes  a  protein  which  is  not
present  in  the  complement  system.32 The  determination  of
these  tests  must  be  carried  out  prior  to  offering  transfusion
treatment  to  these  patients.
Patients  with  complement-mediated  atypical  haemolytic
uraemic  syndrome  present  lower  levels  of  C3  or  C4.  How-
ever,  plasmatic  levels  within  the  C3,  C4,  FCB,  FCH  and  TPI
range  do  not  exclude  diagnosis  of  complement-mediated
atypical  haemolytic  uraemic  syndrome.33
Treatment
Treatment  with  plasmapheresis  or  infusion  of  fresh  frozen
plasma  has  been  the  cornerstone  of  treatment  for  atypical
haemolytic  uraemic  syndrome  since  1980  and  was  essen-
tially  the  only  available  therapy  until  recently;  the  decision
between  one  or  the  other  form  of  therapy  depends  on  the
size  of  the  patient  and  the  extent  of  kidney  failure,  which
limit  the  use  of  transfusion.3 Fresh  frozen  plasma  infu-
sion  infuses  normal  functioning  regulatory  proteins  from  the
alternative  complement  pathway,  whilst  the  intended  us
of  plasma  exchange  is  to  eliminate  the  following:  dysfunc-
tional  proteins,  anti-FCH  antibodies  and  possible  triggers
of  endothelial  aggression  (thrombogenic  or  inﬂammatory
factors).4 In  pregnancy  initial  treatment  is  plasmpheresis
which  is  carried  out  in  the  same  way  as  for  non  pregnant
o
u
T
oatients34,  but  prior  to  initiating  therapy  it  is  recommended
hat  a  viral  panel  be  made  to  exclude  any  infection  before
ransfusion,  and  vaccination  is  even  recommended  in  sus-
eptible  patients.35 The  most  effective  therapeutic  regime
s  unknown,  although  guidelines  of  consensus  recommend
arly  initiation,  to  be  maintained  and  intense,  with  daily
ession  of  plasmapheresis  using  2  plasmatic  volumes  in
dults  and  with  a  gradual  reduction  when  the  platelet  count
s  above  150×109/l  for  at  least  3  days,  and  concentrations
f  lactate  dehydrogenase  are  normal.  If  no  improvement
s  observed  in  a  lapse  of  5  days,  the  administration  of
culizumab  should  be  considered;  if  there  is  some  improve-
ent,  the  interval  should  be  lengthened  to  once  a  week  or
very  two  weeks.35 If  no  plasmapheresis  can  be  initiated  in
he  ﬁrst  24  hours  of  presentation,  fresh  plasma  transfusion
ill  be  initiated  at  a  dose  of  10--20  ml/kg  if  the  patient  shows
o  signs  of  overload  of  volume  or  cardiac  arrest,  and  the
ose  should  be  limited  in  cases  of  hypertension  and  kidney
ailure.  Therapy  duration  and  intervals  between  doses  will
epend  on  the  clinical  evolution  of  each  patient.  In  some
rticles  involving  pregnant  patients,  treatment  continues
ntil  pregnancy  has  run  full  term.35 Although  giving  birth
n  general  will  not  resolve  thrombotic  thrombocytopenic
urpura  and  haemolytic  uraemic  syndrome,  anecdotal  evi-
ence  suggests  that  it  may  do  so  in  some  patients  when
hey  present  with  over-aggregated  preeclampsia.36 If  there
s  response  to  treatment,  pregnancy  should  continue  to  full
erm  with  obstetric  monitoring  and  interruption  of  preg-
ancy  should  be  considered  in  the  case  of  presentation  of
he  alterations  listed  in  Table  2.35--40
In  patients  with  atypical  haemolytic  uraemic  syndrome
hose  response  to  treatment  is  poor,  administration  of
culizumab  should  be  considered.  Its  mechanism  of  action
nhibits  the  complement  pathway,  speciﬁcally  inhibiting  C5
n  the  terminal  complement  pathway.
The  use  of  eculizumab  in  gestational  atypical  haemolytic
raemic  syndrome  is  anecdotal.  In  the  last  10  years  7  articles
ave  been  published  on  its  use,  but  there  is  not  sufﬁcient
vidence  for  its  recommendation  as  ﬁrst  line  treatment.
he  dose  reported  in  literature  is  900  mg  weekly  with  inter-
als  of  2--4  weeks,  without  any  explanation  of  the  cause
f  this  difference  between  the  doses  and  treatment  contin-
es  with  a  maintenance  dose  of  1200  mg  every  7--14  days.
hey  all  report  complete  remission  of  the  syndrome,  with-
ut  no  recurrence  in  6  months  of  follow-up.41--45 In  patients
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Table  2  Indications  for  interruption  of  pregnancy  in  the
atypical  haemolytic  uraemic  syndrome.
Haematological  abnormalities
Thrombocytopenia  or  haemolytic  microangiopathy  which
progresses  despite  treatment
Neurological  abnormalities
Abnormal  mental  status  (confusion,  stupor,  coma,
disorientation)
Focal abnormalities  (aphasia,  dysarthria,  focal  motor
deﬁciencies)
Renal  abnormalities
Acute  renal  failure
Foetal  abnormalities
Signs  of  distress  or  foetal  suffering
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Signs  of  restriction  of  intrauterine  growth
ith  atypical  haemolytic  uraemic  syndrome  and  replace-
ent  prolonged  renal  treatment,  recuperation  of  kidney
unction  is  achieved  with  the  use  of  eculizumab.  There  are
eports  of  clinical  remission  of  the  disease  which  enables
regnancy  to  continue  to  38  weeks  with  no  repercussions  to
ither  foetus  or  mother.
rognosis
his  syndrome  has  a  high  rate  of  morbidity  and  mortality,
ut  early  diagnosis,  correct  monitoring  and  the  right  treat-
ent  improve  prognosis.  Patients  in  whom  alterations  in  C3
ave  been  reported  require  genetic  advice  owing  to  the  risk
f  foetal  loss  and  the  development  of  preeclampsia.  How-
ver,  identiﬁcation  of  this  mutation  does  not  provide  any
rediction  of  the  risk  of  presenting  with  gestational  atypical
aemolytic  uraemic  syndrome,  as  the  genetic  penetration
f  this  disease  is  variable.  Published  data  report  an  over-
ll  penetration  of  50--60%  and  additional  factors,  such  as
lterations  in  FH  and  PCM,  which  are  the  extra  triggers  for
he  development  of  atypical  haemolytic  uraemic  syndrome.
ny  patient,  therefore,  with  complement  alteration  must
e  strictly  monitored  by  an  obstetrician  who  is  experienced
n  high  risk  pregnancy.  Prophylactic  plasmapheresis  should
ot  be  carried  out  during  pregnancy,  when  the  patient  has  a
ackground  of  atypical  haemolytic  uraemic  syndrome,  since
he  risk  of  complications  exceeds  the  beneﬁts  of  an  empiri-
al  treatment.
onclusions
he  progression  and  understanding  of  the  physiopathology
f  atypical  haemolytic  uraemic  syndrome  during  the  last
ecade  has  made  new  treatment  options  possible.  These
ay  prevent  its  evolution  in  high  risk  patients.  As  preg-
ancy  is  a  trigger  of  this  syndrome,  we  believe  it  is  necessary
o  assess  high  risk  patients,  which  makes  it  necessary  to
e  aware  of  the  true  prevalence  of  this  disease  during
regnancy.  Studies  are  needed  on  the  2  current  lines  of
reatment  (plasmapheresis  and  eculizumab)  to  deﬁne  the
ndications  of  both  in  patients  with  this  syndrome  and
1Á.A.  Pérez-Calatayud  et  al.
o  know  how  effective  they  are  in  disease  reversion  as
onotherapy  or  combined  therapy.
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